Novartis Launches Scapho Drug for the Treatment of Psoriasis

by Reshma Anand on  March 18, 2016 at 11:18 AM Corporate News
RSS Email Print This Page Comment bookmark
Font : A-A+

Switzerland-based pharmaceutical company, Novartis has launched the drug, Scapho for the treatment of plaque psoriasis in India.
Novartis Launches Scapho Drug for the Treatment of Psoriasis
Novartis Launches Scapho Drug for the Treatment of Psoriasis

Psoriasis is a severe, non-contagious autoimmune skin disease, characterized by red scaly patches covered with white scales. Plaque psoriasis is a more serious form of the condition.

The generic name of Scapho is secukinumab, which is an injectable medicine and the first interleukin-17A (IL-17A) inhibitor to be approved in India for the treatment of moderate-to-severe plaque psoriasis in adult patients.

The company has launched the drug in the strength of 15mg in India, but it is already available in the US and Europe under the brand name Cosentyx.

"This approval marks a significant milestone in the treatment of psoriasis, providing a new and important first-line biologic treatment option for patients who are candidates for systemic therapy," Novartis said in a statement.

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Drug Toxicity Signature Drug Toxicity Psoriasis Dry Skin Symptom Evaluation Foods that are Bad for your Skin Itchy Scalp Diet for Psoriasis Scalp Psoriasis 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive